CAR T-Cell Therapy in High-Risk Non-Hodgkin Lymphoma

Article

This OncLive® webinar will focus on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma. Join us Tuesday, June 30, 2020 at 7 PM EST.

Date/Time: Tuesday, June 30, 2020 at 7 PM EST

This OncLive® webinar will focus on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma (NHL). Join our leading experts as they discuss important topics and considerations surrounding CAR T-Cell therapy and patients with High-Risk Non-Hodgkin Lymphoma.

Click here to register today!

Course Topics:

  • Rationale for CAR T-Cell therapy in patients with lymphoma
  • Review of CAR T-Cell activity in aggressive lymphoma
  • Review of CAR T-Cell activity in indolent lymphoma and CLL
  • Activity of CAR T-Cell in myeloma
  • Review progress on short term and longer term toxicity of CAR T-Cells
  • Real-world data compared with results seen on clinical trials
  • Navigating referrals in the community
  • Future directions for CAR T-Cell therapy in NHL

Chair
Andre H. Goy, MD
Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer - John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology- Hackensack Meridian School of Medicine at Seton Hall University
Professor of Medicine – Georgetown University
Hackensack, NJ

Sponsored by:

Related Videos
A panel of 4 experts on hematologic malignancies
A panel of 4 experts on chronic graft-versus-host disease
A panel of 4 experts on chronic graft-versus-host disease
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
James K. McCloskey, MD, an expert on leukemia
James K. McCloskey, MD, an expert on leukemia
Amy DeZern, MD, MHS, an expert on MDS